Events

SHERIDAN, WYOMING – May 5, 2025 – Tower Health and Siemens Healthineers have entered a decade-long Value Partnership designed to modernize diagnostic imaging capabilities, enhance operational efficiency, and support long-term clinical excellence across the Tower Health network. The multi-faceted alliance marks a strategic investment in state-of-the-art technology and digital tools aimed at elevating patient care in radiology, oncology, and cardiology services.

Driving Long-Term Value Through Technological Modernization

The 10-year Value Partnership is more than a procurement agreement; it is a strategic roadmap to elevate Tower Health’s infrastructure through lifecycle management and standardization of advanced imaging equipment. The collaboration will bring cutting-edge Siemens Healthineers solutions to Tower Health, including:

SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has announced encouraging 3-month results from its pivotal Omny-IRE clinical trial, spotlighting the high-performance capabilities of its investigational OMNYPULSE™ Platform. Unveiled during the 2025 Heart Rhythm Society (HRS) Annual Meeting and simultaneously published in JACC Clinical Electrophysiology, the findings mark a strategic milestone in the company’s pulsed field ablation (PFA) portfolio expansion, with significant implications for patient care, procedural efficiency, and technology adoption in electrophysiology.

Breakthrough Results from the Omny-IRE Trial

SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has announced the presentation of 22 sponsored or funded clinical studies at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego, showcasing its continued leadership in the electrophysiology space. The company’s expansive dataset highlights innovation in pulsed field ablation (PFA) technologies, real-world treatment strategies, and critical insights from the REAL-AF Registry and Patient Care Pathways and Outcomes study—reinforcing its commitment to evidence-based care and better patient outcomes.

Driving Strategic Innovation in Cardiac Electrophysiology

SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has marked a significant milestone in the evolution of robotic-assisted surgery by completing the first clinical trial cases of its OTTAVA™ Robotic Surgical System. This development positions the company at the forefront of innovation in minimally invasive procedures, reinforcing its strategic commitment to delivering cutting-edge surgical technologies that raise standards in operating rooms worldwide.

Strategic Leap in Robotic-Assisted Surgery

The inaugural clinical cases for the OTTAVA system were led by Dr. Erik Wilson, Chief of Minimally Invasive and Elective General Surgery at UT Health Houston, who performed Roux-en-Y gastric bypass surgeries at Memorial Hermann-Texas Medical Center. These procedures represent the first real-world clinical application of the OTTAVA system and a pivotal moment in its developmental journey.

SHERIDAN, WYOMING – May 5, 2025 – Shockwave Medical, Inc., a Johnson & Johnson MedTech company and global leader in circulatory restoration, has officially initiated its FORWARD CAD Investigational Device Exemption (IDE) study. This pivotal research effort will evaluate the safety and efficacy of the Shockwave Javelin Coronary IVL Catheter for the treatment of difficult-to-cross, heavily calcified coronary artery lesions—an area with high unmet clinical need and procedural risk.

The first patient in the study was successfully treated by Dr. Evan Shlofmitz and Dr. Ziad Ali at St. Francis Hospital & The Heart Center in Roslyn, New York. This milestone underscores the growing clinical interest in Shockwave’s forward IVL (intravascular lithotripsy) platform as a potential alternative to atherectomy, especially in complex percutaneous coronary interventions (PCI).

Advancing Treatment for Challenging Coronary Artery Disease

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for its Simplera Sync™ sensor, marking a significant expansion of its continuous glucose monitoring (CGM) portfolio in the United States. The approval enables integration of the Simplera Sync™ sensor with the company’s flagship MiniMed™ 780G system, offering greater flexibility and convenience to people managing diabetes through advanced insulin delivery technology.

Strategic Advancement in Diabetes Care Technology

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has officially submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) for its MiniMed™ 780G pump and SmartGuard™ algorithm, paving the way for seamless integration with Abbott’s advanced continuous glucose monitoring (CGM) platform. This critical regulatory milestone strengthens Medtronic’s strategic partnership with Abbott and positions the company to deliver more interoperable, intelligent diabetes care solutions to the U.S. market.

Accelerating Innovation Through Strategic Interoperability

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure™ defibrillation lead—the smallest-diameter, catheter-delivered defibrillation lead for right ventricular implantation. This approval marks a major advancement in cardiac rhythm management, offering physicians a less invasive, highly durable solution to treat life-threatening arrhythmias in both adults and adolescents with smaller anatomies.

Strategic Advancement in Cardiac Rhythm Management

The FDA’s green light for the OmniaSecure lead strengthens Medtronic’s leadership in electrophysiology and expands its robust portfolio of transvenous lead solutions. At only 4.7 French (1.6mm) in diameter, the OmniaSecure lead builds on the proven SelectSecure™ Model 3830 pacing lead platform, already widely adopted in the clinical community for over two decades.

SHERIDAN, WYOMING – May 5, 2025 – Medtronic has announced a major milestone for its Hugo™ robotic-assisted surgery (RAS) system, as the Expand URO U.S. clinical trial met both primary safety and effectiveness endpoints. The results position the company for strategic market entry into the U.S. robotic-assisted surgery sector, the largest of its kind globally, and were presented as a late-breaking session at the American Urologic Association (AUA) annual meeting in Las Vegas.

Landmark Trial Sets New Benchmark in Robotic Urologic Surgery

The Expand URO study is the largest Investigational Device Exemption (IDE) trial conducted in the U.S. for multi-port robotic-assisted urologic procedures. Designed as a prospective, multi-center, single-arm study, it involved 137 patients across six hospitals. Participants underwent one of three common urologic surgeries — prostatectomy, nephrectomy, or cystectomy — using the Hugo RAS system.

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT) has announced encouraging one-year clinical outcomes for its investigational Affera™ pulsed field ablation (PFA) technologies, reinforcing its strategic leadership in arrhythmia management. The results—revealed at the Heart Rhythm Society 2025 Annual Meeting—highlight the performance of the next-generation Sphere-360™ single-shot PFA catheter and the dual-energy Sphere-9™ catheter in treating patients with paroxysmal and persistent atrial fibrillation (AFib), one of the world’s most prevalent cardiac rhythm disorders.

Sphere-360™ Demonstrates Safety, Efficiency, and Superior Mapping Integration

The Sphere-360 catheter, part of the Affera ecosystem, is engineered as a single-shot PFA mapping and ablation tool designed specifically for paroxysmal AFib. In a European-based, multi-center clinical trial, the technology achieved:

SHERIDAN, WYOMING - May 5, 2025 - In the evolving landscape of restorative dentistry, post-endodontic restoration has emerged as a cornerstone of long-term tooth preservation strategies, offering clinicians and patients alike a pathway to restore function, aesthetics, and durability following root canal therapy. New insights from recent clinical literature highlight the increasing relevance of this specialized restorative approach for practitioners focused on optimizing patient outcomes and return on investment in dental care.

Driving Longevity Through Strategic Restoration

SHERIDAN, WYOMING - May 5, 2025 - In a dental landscape increasingly dominated by minimally invasive approaches, orthognathic surgery-supported by pre- and post-surgical orthodontics-is regaining prominence as a critical solution for addressing complex skeletal deformities that fall beyond the scope of traditional orthodontics.

This resurgent interest is not merely cosmetic. When aesthetic, functional, and long-term stability outcomes are considered, orthognathic surgery emerges as a high-ROI treatment path for select cases. It effectively bridges orthodontic limitations by offering predictable, stable results where skeletal discrepancies compromise both occlusion and facial harmony.

Orthognathic Surgery: A Modern Answer to Structural Challenges

SHERIDAN, WYOMING - May 5, 2025 - The integration of digital technology in dentistry is revolutionizing how dental professionals approach aesthetic treatments, offering enhanced predictability, improved patient engagement, and cross-disciplinary collaboration-while also presenting operational and financial challenges for broader adoption.

Once a futuristic concept, digital dentistry has now become a foundational component in modern dental practices. With advanced software tools like Digital Smile Design (DSD) and the Digital Smile System enabling highly personalized smile simulations, the field is experiencing a strategic shift that enhances both patient outcomes and clinical efficiency.

Transforming Smile Design Through Digital Innovation

SHERIDAN, WYOMING – May 5, 2025 – As dental clinics across the globe continue to strengthen their infection control protocols, the proper use of disinfectants remains a cornerstone of safety. While these products play a pivotal role in preventing cross-infections, recent analyses underscore the need for heightened awareness of the associated chemical and biological risks—making the responsible use of dental disinfectants a strategic imperative for operational safety and compliance.

Balancing Infection Control with Occupational Safety

Cross-infection continues to rank among the most serious complications in healthcare settings, impacting up to 10% of hospitalized patients and generating a staggering annual cost of approximately $4.5 billion in the United States. Though precise figures for dental environments remain difficult to quantify, the threat is real—extending from patients to staff and even external technicians.

SHERIDAN, WYOMING – May 5, 2025 – Ecosite Elements, a leading composite restorative solution, has been prominently featured in the May 2025 issue of Inside Dentistry, spotlighting its clinical effectiveness through a comprehensive case report authored by Dr. Jeff Lineberry. The report highlights a 32-year-old patient presenting with multiple anterior tooth fractures, successfully treated using Ecosite Elements for a highly esthetic and functional outcome.

This feature underscores Ecosite Elements’ growing reputation among dental professionals as a go-to choice for restorative excellence. With a focus on esthetics, efficiency, and material adaptability, the case study demonstrates how modern composite technologies are transforming chairside outcomes and supporting better long-term patient care.

Clinical Precision and Esthetic Performance

SHERIDAN, WYOMING – May 5, 2025 – Dental professionals seeking to enhance their clinical expertise in micro-invasive treatments can now register for a complimentary continuing education (CE) webinar titled “Mastering Resin Infiltration for Predictable Results”, hosted by industry leader Irene Iancu, BSc, RRDH, CTDP, OM. The session, scheduled for June 17, 2025, at 7PM ET, offers one CE credit and delivers a strategic deep dive into the resin infiltration technique using DMG’s Icon system.

Enhancing Practice Outcomes Through Resin Infiltration

Resin infiltration has emerged as a game-changing alternative in the conservative treatment of early carious lesions, providing dentists and hygienists with an advanced, esthetically favorable approach. This CE webinar is designed to help professionals incorporate this micro-invasive procedure into their clinical workflow with confidence and predictability.

SHERIDAN, WYOMING - May 5, 2025 - A recent patient testimonial is shining new light on the clinical and commercial value of DentaMile Bleaching Trays by DMG, positioning the solution as a game-changer in cosmetic dentistry. With a combination of 3D-printed precision and patient-centric design, the whitening trays are redefining the standard for comfort, efficiency, and aesthetic outcomes.

Patient-Driven Results Strengthen Clinical Appeal

In a compelling new video, a patient candidly shares their experience with DentaMile Bleaching Trays, highlighting standout benefits such as comfort and efficacy. Traditional whitening methods, often plagued by discomfort and uneven results, are increasingly being outpaced by advanced, tech-enabled alternatives. DentaMile's approach eliminates the guesswork by offering a digitally designed, custom-fitted tray that optimizes whitening while minimizing sensitivity.

SHERIDAN, WYOMING – May 5, 2025 – Shofu’s EyeSpecial C-II Digital Dental Camera has been named the 2014 Best New Product for Women by the American Association of Women Dentists (AAWD), marking a strategic milestone in dental imaging technology and its alignment with the evolving needs of modern dental practices. Recognized at AAWD’s Annual Meeting, themed “Leading the Future of Dentistry”, the camera stood out for its blend of ergonomic design, clinical functionality, and user-focused features—particularly appealing to women dentists and their patients.

Purpose-Built for Dental Professionals

SHERIDAN, WYOMING – May 5, 2025 – Shofu Dental Corporation has unveiled its new Attachment Removal Kit for Clear Aligners, offering dental professionals a complete, minimally invasive solution for safely removing orthodontic attachments while preserving enamel integrity—addressing a critical challenge in clear aligner therapy.

With the continued growth of clear aligner systems such as Invisalign across the global orthodontic market, practitioners are seeking tools that balance clinical efficiency with patient comfort and safety. Shofu’s new kit delivers precisely that, streamlining a procedure often marked by concerns over enamel damage, chairside time, and patient discomfort.

A Strategic Leap in Clear Aligner Care

SHERIDAN, WYOMING – May 5, 2025 – Carestream Dental is setting a new benchmark in digital dental technology with the debut of its latest solutions at the 2025 Chicago Dental Society Midwinter Meeting, including the Advance Edition of the CS 8200 3D system, a next-generation implant planning service, and AI-powered software integrations. These innovations reflect the company’s ongoing commitment to empowering dental professionals with tools that drive operational efficiency, precision, and confidence in care delivery.

Expanded CBCT Capabilities with the CS 8200 3D Advance Edition

A focal point of Carestream Dental’s announcement is the Advance Edition of the CS 8200 3D, a powerful evolution of the award-winning CS 8200 3D Family. Engineered for versatility and scalability, the Advance Edition introduces extended fields of view (FOVs) and advanced artificial intelligence functionalities that cater to a wide spectrum of clinical needs.